Cardiogenic shock
Not recruitingStudy on Istaroxime for Patients with Cardiogenic Shock Stage C
- Disease:Cardiogenic shock
- Substances:Istaroxime
Czechia- Participants:18–64 years · 65+ years
- Substances:Istaroxime
- Sponsor:Windtree Therapeutics Inc.
Rare diseases
Investigational molecules
Locations
2600 Kelly Road Suite 100, 18976-3652, United States
Windtree Therapeutics Inc. focuses on cardiogenic shock, with particular interest in patients experiencing severe circulatory compromise during acute decompensated heart failure. The research activity centers on restoring systolic blood pressure and improving hemodynamic stability in SCAI Stage C presentations.
The sponsor’s clinical interest is concentrated on hospitalized patients with persistent hypotension who require targeted cardiovascular support.
Windtree Therapeutics Inc. runs clinical trials in conditions such as Cardiogenic shock, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
CzechiaIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.